In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

Daniel L. Suzman, Emmanuel S. Antonarakis

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis'. Together they form a unique fingerprint.